• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Praxis Precision Medicines Inc.

    5/15/26 1:17:33 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRAX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Praxis Precision Medicines, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)




    74006W207

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    74006W207


    1Names of Reporting Persons

    ORBIS INVESTMENT MANAGEMENT LTD
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    BERMUDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,468,413.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,468,413.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,468,413.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.9 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    CUSIP Number(s):
    74006W207


    1Names of Reporting Persons

    Allan Gray Australia Pty Ltd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    AUSTRALIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,067.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,067.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,067.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Praxis Precision Medicines, Inc.
    (b)Address of issuer's principal executive offices:

    99 HIGH STREET, 30TH FLOOR, BOSTON, MASSACHUSETTS 02110
    Item 2. 
    (a)Name of person filing:

    ORBIS INVESTMENT MANAGEMENT LTD Allan Gray Australia Pty Ltd
    (b)Address or principal business office or, if none, residence:

    ORBIS INVESTMENT MANAGEMENT LTD: Orbis House, 25 Front Street, Hamilton, Bermuda HM11 Allan Gray Australia Pty Ltd: Level 2, Challis House, 4 Martin Place, Sydney NSW2000, Australia
    (c)Citizenship:

    ORBIS INVESTMENT MANAGEMENT LTD - BERMUDA Allan Gray Australia Pty Ltd - AUSTRALIA
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    74006W207
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Equivalent to IA.
    Item 4.Ownership
    (a)Amount beneficially owned:

    2,472,480
    (b)Percent of class:

    8.9  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    ORBIS INVESTMENT MANAGEMENT LTD - 2,468,413 Allan Gray Australia Pty Ltd - 4,067

     (ii) Shared power to vote or to direct the vote:

    ORBIS INVESTMENT MANAGEMENT LTD - 0 Allan Gray Australia Pty Ltd - 0

     (iii) Sole power to dispose or to direct the disposition of:

    ORBIS INVESTMENT MANAGEMENT LTD - 2,468,413 Allan Gray Australia Pty Ltd - 4,067

     (iv) Shared power to dispose or to direct the disposition of:

    ORBIS INVESTMENT MANAGEMENT LTD - 0 Allan Gray Australia Pty Ltd - 0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Other persons have the right to receive dividends from, the power to direct the receipt of dividends from, or the right to receive the proceeds from the sale of, the securities of the issuer identified in Item 4(a) that are beneficially owned by Orbis Investment Management Ltd. Another person has the right to receive dividends from, the power to direct the receipt of dividends from, or the right to receive the proceeds from the sale of, the securities of the issuer identified in Item 4(a) that are beneficially owned by Allan Gray Australia Pty Ltd.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    Information with respect to each of Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd (collectively, the "Reporting Persons") is given solely by each such Reporting Person and no Reporting Person has responsibility for the accuracy or completeness of information supplied by any other Reporting Person. Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd are classified as a Non-U.S. Institution (FI) that is equivalent to an Investment Adviser (IA). Notwithstanding that the Reporting Persons are making this filing together, none of the Reporting Persons represents that it is a member of a group for the purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended. Each Reporting Person disclaims beneficial ownership of any shares beneficially owned by any other Reporting Person as specified in Item 4(a).
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    ORBIS INVESTMENT MANAGEMENT LTD
     
    Signature:Matthew Gaarder
    Name/Title:Attorney-in-Fact
    Date:05/15/2026
     
    Allan Gray Australia Pty Ltd
     
    Signature:Matthew Gaarder
    Name/Title:Attorney-in-Fact
    Date:05/15/2026
    Get the next $PRAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRAX

    DatePrice TargetRatingAnalyst
    4/10/2026$815.00Strong Buy
    Raymond James
    2/24/2026$500.00Outperform
    Wolfe Research
    2/2/2026$282.00Equal Weight
    Wells Fargo
    12/15/2025$250.00 → $750.00Outperform
    Oppenheimer
    11/19/2025$424.00Buy
    BTIG Research
    6/2/2025$97.00Outperform
    Oppenheimer
    5/7/2025$80.00Buy
    Chardan Capital Markets
    3/3/2025$120.00 → $105.00Buy
    H.C. Wainwright
    More analyst ratings

    $PRAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Accounting Officer Mastrocola Lauren was granted 127 shares, increasing direct ownership by 0.94% to 13,573 units (SEC Form 4)

    4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

    5/19/26 9:45:41 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel and Secretary Nemiroff Alex was granted 78 shares, increasing direct ownership by 0.30% to 26,011 units (SEC Form 4)

    4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

    5/19/26 9:45:18 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Kelly Timothy Edwin was granted 121 shares, increasing direct ownership by 0.39% to 31,167 units (SEC Form 4)

    4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

    5/19/26 9:44:39 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on Praxis Precision Medicines with a new price target

    Raymond James initiated coverage of Praxis Precision Medicines with a rating of Strong Buy and set a new price target of $815.00

    4/10/26 8:34:55 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Praxis Precision Medicines with a new price target

    Wolfe Research initiated coverage of Praxis Precision Medicines with a rating of Outperform and set a new price target of $500.00

    2/24/26 7:55:37 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Praxis Precision Medicines with a new price target

    Wells Fargo initiated coverage of Praxis Precision Medicines with a rating of Equal Weight and set a new price target of $282.00

    2/2/26 6:51:57 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Desimone Jill bought $25,375 worth of shares (14,500 units at $1.75) (SEC Form 4)

    4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

    10/10/23 7:41:39 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    SEC Filings

    View All

    Praxis Precision Medicines Inc. filed SEC Form 8-K: Other Events

    8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)

    6/1/26 4:28:49 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Praxis Precision Medicines Inc.

    SCHEDULE 13G - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    5/15/26 4:17:33 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Praxis Precision Medicines Inc.

    SCHEDULE 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    5/15/26 4:15:45 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on June 1, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 2,754 shares of its common stock to thirteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). Th

    6/2/26 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Provides Vormatrigine Program Update

    POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second half of the study on higher dose (30 mg) was more pronounced Vormatrigine was generally well-tolerated; adverse event-related discontinuations were less than 10% Approximately 90% of patients from the vormatrigine arm transitioned to and remain in the open label extension (OLE) study Praxis is pausing enrollment in the POWER2 study to reassess the vormatrigine program and determine potential modifications BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ

    6/1/26 4:15:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

    FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) with a PDUFA target action date of September 27, 2026 EMBRAVE Part A study results showed elsunersen treatment led to a 77% placebo-adjusted reduction in monthly seizures and demonstrated disease-modifying improvements in patients with early-seizure onset SCN2A-DEE Topline results from the POWER1 study of vormatrigine in focal onset seizures expected in Q2 2026 Recruiting completed for relutrigine EMERALD study in broad DEEs, with top

    5/7/26 8:00:00 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 7:53:30 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 5:50:15 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 5:46:12 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Leadership Updates

    Live Leadership Updates

    View All

    Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

    BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the appointment of world-renowned neurologist and epilepsy authority Dr. Orrin Devinsky, M.D., as Head of Clinical Strategy, a newly created leadership role. Dr. Devinsky is widely regarded as one of the most influential physician-scientists of his generation in modern epilepsy and clinical neuroscience. Over a career spanning more than four decades, he has shaped the development of multiple transformative therapies, built enduring global research initiatives, and helped define t

    1/13/26 4:30:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

    BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation–inhibition imbalance, today announced the appointment of Jeffrey B. Kindler and Stuart Arbuckle to its board of directors, and the promotions of Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President of Research & Development. "These leadership decisions reflect a deliberate evolution of Praxis as we enter a phase driven by commercial launch planning and execution readiness, late-stage developm

    1/8/26 4:45:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results

    PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming biomarker change and potential for wide therapeutic window Cash and investments of $165.4 million as of June 30, 2022 supports runway into 1Q24 BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the second quarter of 2022

    8/8/22 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Financials

    Live finance-specific insights

    View All

    Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

    BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the first quarter ended March 31, 2026, and provide a corporate update before the financial markets open on Thursday, May 7, 2026. The Company will host a conference call and a live webcast to review the first quarter financial results and provide a corporate update on Thursday, May 7, 2026, at 8:30 am ET, which can be accessed by visiting this registration link. The live webcast will also be available on the Events & Presentations page of

    5/4/26 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

    BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a corporate update before the financial markets open on Thursday, February 19, 2026. The Company will host a conference call and a live webcast to review the fourth quarter financial results and provide a corporate update on Thursday, February 19, 2026, at 8:00 am ET, which can be accessed by visiting this registration link. The live webcast will also be available on the

    2/9/26 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results

    RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in seizure frequency from baseline, with 22% at 100% seizure reduction in last 28 days Initiated two registrational studies for Developmental and Epileptic Encephalopathies (DEEs) programs: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A Gain-of-Function (GoF) with elsunersen Relutrigine granted U.S. FDA Breakthrough Therapy Designation for the treatment of seizures associated with SCN2A and SCN8A DEEs, enabling expedited development Cash and investments of approximately $447 million as of June 30, 2025 maintains runway into 2028 Praxi

    8/4/25 8:30:00 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care